2 citations · 2 across the 5 of their papers we have counts for
5 papers
Next generation clinical trials: Seamless designs and master protocols
Abigail Burdon, Thomas Jaki, Xijin Chen +3
Background: Drug development is often inefficient, costly and lengthy, yet it is essential for evaluating the safety and efficacy of new interventions. Compared with other disease…
Multivariate group sequential tests for global summary statistics
Abigail J. Burdon, Thomas Jaki
We describe group sequential tests which efficiently incorporate information from multiple endpoints allowing for early stopping at pre-planned interim analyses. We formulate a tes…
The use of restricted mean survival time to estimate treatment effect under model misspecification, a simulation study
Emily Alger, David S. Robertson, Abigail J. Burdon
The use of the non-parametric Restricted Mean Survival Time endpoint (RMST) has grown in popularity as trialists look to analyse time-to-event outcomes without the restrictions of…
Adaptive enrichment trial designs using joint modeling of longitudinal and time-to-event data
Abigail J. Burdon, Richard D. Baird, Thomas Jaki
Adaptive enrichment allows for pre-defined patient subgroups of interest to be investigated throughout the course of a clinical trial. Many trials which measure a long-term time-to…
Joint modelling of longitudinal and time-to-event data applied to group sequential clinical trials
Abigail J. Burdon, Lisa V. Hampson, Christopher Jennison
Often in Phase 3 clinical trials measuring a long-term time-to-event endpoint, such as overall survival or progression-free survival, investigators also collect repeated measures o…